Psyomics Reviews & Product Details

Psyomics Ltd are transforming the Mental Health Triage and Assessment process. Sitting at the front door to Mental Health services, their Censeo platform is an adaptive questionnaire that gives a personalised experience to the service user. Asking questions and gathering information on their current symptoms, probing further where symptoms are found and efficiently moving on where they are not. This creates a symptom profile across 15 common mental health conditions which reduces clinical admin, supports MDT decision making, and improves consistency across all front doors. It also supports selecting the correct pathway, first time. The report produced for clinicians brings simplicity to an incredibly complicated cohort of people, creating a single summary page that shows the triage priority, the symptoms profile, and the demographic information of the person; all within the electronic record. This summary is interactive and the full detail gathered is never more than one click away, all categorised and grouped in a way that makes sense to clinicians. Examples of the impacts it can have include; significantly reducing the clinical time needed in the assessment process, highlighting poorly diagnosed conditions at the front door (e.g. Bipolar, rather than the 9.5yr average), and seeing the interplay of conditions (e.g. high levels of depression may actually be related to Trauma). The benefits to the service user include being able to complete difficult and probing questions at your own pace and in your own space (25% complete the personalised questionnaire between 8pm-6am), feeling prepared for treatment (having experienced the DSM-5 and ICD-11 informed questions), and having the chance to think about questions before answering them (often completing the questionnaire in 2-3 sittings). Psyomics is led by Consultant Clinical Psychologist CEO Dr Melinda Rees. In conjunction with Cambridge University and founder Professor Sabine Bahn, Psyomics’ AI-informed platform - Censeo - was borne from more than six years of research and development. Psyomics maintains its relationship with Cambridge, continually researching its products and Professor Sabine Bahn continues to be the lead for the Neurodivergence Labs at Cambridge University. The 15 conditions currently covered include; Bipolar I, Bipolar II, Psychotic symptoms, Disordered Eating, Alcohol use, Substance Abuse, Adjustment Disorder, Major Depressive Disorder, Generalised Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Obsessive Compulsive Disorder, Insomnia, Emotional Instability, and Trauma. On the roadmap are ADHD, ASD and a new CYP version targeted for Q3 2025.